Spark’s price for Luxturna blindness gene therapy too high: ICER

Share this post

(Reuters) – The proposed price for Spark Therapeutics Inc’s groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply